Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE0116 and PE0105 in Advanced Solid Tumors
NCT05801237Phase 2Recruiting
- Sponsor
- Shanghai HyaMab Biotechnology
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PE0116, PE0105 in solid tumor, sponsored by Shanghai HyaMab Biotechnology. Started Sep 2023; status: recruiting.
02
Drugs
PE0116PE0105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05801237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801237.